{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '8045 Lamon Avenue',
 'address2': 'Suite 410',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.3,
 'askSize': 3200,
 'averageDailyVolume10Day': 177700,
 'averageVolume': 386182,
 'averageVolume10days': 177700,
 'beta': 1.683116,
 'beta3Year': None,
 'bid': 2.31,
 'bidSize': 45900,
 'bookValue': 0.977,
 'category': None,
 'circulatingSupply': None,
 'city': 'Skokie',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.38,
 'dayLow': 2.3,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.126,
 'enterpriseToRevenue': 9.833,
 'enterpriseValue': 102792536,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '847 556 6411',
 'fiftyDayAverage': 2.6135714,
 'fiftyTwoWeekHigh': 3.84,
 'fiftyTwoWeekLow': 0.957,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 70093362,
 'forwardEps': -0.4,
 'forwardPE': -5.7749996,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.23437001,
 'heldPercentInstitutions': 0.46694002,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/exicuretx.com',
 'longBusinessSummary': 'Exicure, Inc., a clinical-stage biotechnology '
                        'company, develops therapeutics for immuno-oncology, '
                        'genetic disorders, and other indications. Its three '
                        'clinical programs include AST-008, which is in a '
                        'Phase I clinical trial, an SNA consisting of '
                        'toll-like receptor 9 that is designed for '
                        'immuno-oncology applications; XCUR17, which is in a '
                        'Phase I clinical trial, an SNA that targets the '
                        'messenger RNA (mRNA) encoding interleukin 17 receptor '
                        'alpha, a protein that helps in the initiation and '
                        'maintenance of psoriasis; and AST-005, which is in a '
                        'Phase I clinical trial, an SNA that targets TNF for '
                        'the treatment of mild to moderate psoriasis. Exicure, '
                        'Inc. has collaboration agreements with Allergan plc; '
                        'DERMELIX, LLC; and Purdue Pharma L.P. The company was '
                        'founded in 2011 and is headquartered in Skokie, '
                        'Illinois.',
 'longName': 'Exicure, Inc.',
 'market': 'us_market',
 'marketCap': 201317424,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_82271676',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -19867000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.32,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '847 673 1700',
 'previousClose': 2.35,
 'priceHint': 4,
 'priceToBook': 2.3643806,
 'priceToSalesTrailing12Months': 19.257454,
 'profitMargins': -1.9004201,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.38,
 'regularMarketDayLow': 2.3,
 'regularMarketOpen': 2.32,
 'regularMarketPreviousClose': 2.35,
 'regularMarketPrice': 2.32,
 'regularMarketVolume': 106445,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 87150400,
 'sharesPercentSharesOut': 0.0148,
 'sharesShort': 1290122,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4188,
 'shortName': 'Exicure, Inc.',
 'shortPercentOfFloat': 0.0195,
 'shortRatio': 1.69,
 'startDate': None,
 'state': 'IL',
 'strikePrice': None,
 'symbol': 'XCUR',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.294,
 'twoHundredDayAverage': 2.268813,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ee4bcb27-f318-38c7-8572-459785e7d845',
 'volume': 106445,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.exicuretx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '60077'}